JP2011507542A - 核酸のハイブリダイズ法 - Google Patents
核酸のハイブリダイズ法 Download PDFInfo
- Publication number
- JP2011507542A JP2011507542A JP2010540181A JP2010540181A JP2011507542A JP 2011507542 A JP2011507542 A JP 2011507542A JP 2010540181 A JP2010540181 A JP 2010540181A JP 2010540181 A JP2010540181 A JP 2010540181A JP 2011507542 A JP2011507542 A JP 2011507542A
- Authority
- JP
- Japan
- Prior art keywords
- oligonucleotide
- nucleic acid
- oligocation
- conjugate
- target nucleic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 43
- 238000007899 nucleic acid hybridization Methods 0.000 title description 3
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 57
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 57
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 57
- 108091034117 Oligonucleotide Proteins 0.000 claims abstract description 27
- PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical group NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 claims abstract description 22
- 125000005647 linker group Chemical group 0.000 claims abstract description 11
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical group NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 claims abstract description 8
- 125000002947 alkylene group Chemical group 0.000 claims abstract description 7
- 239000003550 marker Substances 0.000 claims abstract description 6
- KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical group NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 claims abstract description 6
- 229940063673 spermidine Drugs 0.000 claims abstract description 4
- 239000005700 Putrescine Substances 0.000 claims abstract description 3
- 239000000523 sample Substances 0.000 claims description 94
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 29
- 230000003321 amplification Effects 0.000 claims description 27
- 238000003556 assay Methods 0.000 claims description 14
- 238000003753 real-time PCR Methods 0.000 claims description 13
- 238000001514 detection method Methods 0.000 claims description 11
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 10
- 238000010839 reverse transcription Methods 0.000 claims description 8
- 108090000623 proteins and genes Proteins 0.000 claims description 7
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 claims description 6
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 claims description 6
- 238000001668 nucleic acid synthesis Methods 0.000 claims description 6
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims description 6
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 claims description 5
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 claims description 5
- 229960002685 biotin Drugs 0.000 claims description 5
- 235000020958 biotin Nutrition 0.000 claims description 5
- 239000011616 biotin Substances 0.000 claims description 5
- 150000001841 cholesterols Chemical class 0.000 claims description 5
- 230000002209 hydrophobic effect Effects 0.000 claims description 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 5
- 102000004169 proteins and genes Human genes 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 5
- 239000000427 antigen Substances 0.000 claims description 4
- 108091007433 antigens Proteins 0.000 claims description 4
- 102000036639 antigens Human genes 0.000 claims description 4
- 235000000346 sugar Nutrition 0.000 claims description 4
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims description 4
- WSNMPAVSZJSIMT-UHFFFAOYSA-N COc1c(C)c2COC(=O)c2c(O)c1CC(O)C1(C)CCC(=O)O1 Chemical compound COc1c(C)c2COC(=O)c2c(O)c1CC(O)C1(C)CCC(=O)O1 WSNMPAVSZJSIMT-UHFFFAOYSA-N 0.000 claims description 2
- 108091028664 Ribonucleotide Proteins 0.000 claims description 2
- 238000007385 chemical modification Methods 0.000 claims description 2
- 239000005547 deoxyribonucleotide Substances 0.000 claims description 2
- 125000002637 deoxyribonucleotide group Chemical group 0.000 claims description 2
- 239000002336 ribonucleotide Substances 0.000 claims description 2
- 125000002652 ribonucleotide group Chemical group 0.000 claims description 2
- 238000006467 substitution reaction Methods 0.000 claims description 2
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 1
- 101710098119 Chaperonin GroEL 2 Proteins 0.000 claims 1
- 238000002944 PCR assay Methods 0.000 claims 1
- 238000007837 multiplex assay Methods 0.000 claims 1
- 238000009396 hybridization Methods 0.000 abstract description 23
- 150000004713 phosphodiesters Chemical class 0.000 abstract 1
- 108020004414 DNA Proteins 0.000 description 31
- 238000006243 chemical reaction Methods 0.000 description 22
- 210000004027 cell Anatomy 0.000 description 15
- 108091093088 Amplicon Proteins 0.000 description 11
- 230000002441 reversible effect Effects 0.000 description 11
- 230000009977 dual effect Effects 0.000 description 8
- 238000000137 annealing Methods 0.000 description 7
- 125000003729 nucleotide group Chemical group 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 102000008178 Cyclin B1 Human genes 0.000 description 6
- 108010060385 Cyclin B1 Proteins 0.000 description 6
- 241000341655 Human papillomavirus type 16 Species 0.000 description 6
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Chemical class Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 239000002773 nucleotide Substances 0.000 description 5
- 230000035945 sensitivity Effects 0.000 description 5
- 238000013207 serial dilution Methods 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 101000926206 Homo sapiens Putative glutathione hydrolase 3 proenzyme Proteins 0.000 description 4
- 101710163270 Nuclease Proteins 0.000 description 4
- 102100034060 Putative glutathione hydrolase 3 proenzyme Human genes 0.000 description 4
- 238000011529 RT qPCR Methods 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000010791 quenching Methods 0.000 description 4
- 230000000171 quenching effect Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 229940063675 spermine Drugs 0.000 description 4
- BZTDTCNHAFUJOG-UHFFFAOYSA-N 6-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BZTDTCNHAFUJOG-UHFFFAOYSA-N 0.000 description 3
- 101100297345 Caenorhabditis elegans pgl-2 gene Proteins 0.000 description 3
- 101100297347 Caenorhabditis elegans pgl-3 gene Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 108010014172 Factor V Proteins 0.000 description 3
- 238000009004 PCR Kit Methods 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 230000000875 corresponding effect Effects 0.000 description 3
- 239000007850 fluorescent dye Substances 0.000 description 3
- 150000008300 phosphoramidites Chemical class 0.000 description 3
- 229920000768 polyamine Polymers 0.000 description 3
- 238000003762 quantitative reverse transcription PCR Methods 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- 102100034343 Integrase Human genes 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000010804 cDNA synthesis Methods 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 238000003205 genotyping method Methods 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 238000002515 oligonucleotide synthesis Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- 208000018565 Hemochromatosis Diseases 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 238000010802 RNA extraction kit Methods 0.000 description 1
- CGNLCCVKSWNSDG-UHFFFAOYSA-N SYBR Green I Chemical compound CN(C)CCCN(CCC)C1=CC(C=C2N(C3=CC=CC=C3S2)C)=C2C=CC=CC2=[N+]1C1=CC=CC=C1 CGNLCCVKSWNSDG-UHFFFAOYSA-N 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 150000002009 diols Chemical class 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 108010091897 factor V Leiden Proteins 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000010380 label transfer Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 238000007403 mPCR Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- -1 whole genomes Chemical class 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6832—Enhancement of hybridisation reaction
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Analytical Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Crystallography & Structural Chemistry (AREA)
- Plant Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US914507P | 2007-12-27 | 2007-12-27 | |
| EP07025148A EP2075342A1 (en) | 2007-12-27 | 2007-12-27 | Method for hybridizing nucleic acids |
| PCT/IB2008/002789 WO2009083763A1 (en) | 2007-12-27 | 2008-09-12 | Method for hybridizing nucleic acids |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011507542A true JP2011507542A (ja) | 2011-03-10 |
| JP2011507542A5 JP2011507542A5 (enExample) | 2011-09-15 |
Family
ID=39339663
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010540181A Pending JP2011507542A (ja) | 2007-12-27 | 2008-09-12 | 核酸のハイブリダイズ法 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US8465920B2 (enExample) |
| EP (2) | EP2075342A1 (enExample) |
| JP (1) | JP2011507542A (enExample) |
| KR (1) | KR20100124705A (enExample) |
| CN (1) | CN101978071A (enExample) |
| AU (1) | AU2008345460A1 (enExample) |
| BR (1) | BRPI0821698A2 (enExample) |
| CA (1) | CA2709183A1 (enExample) |
| DK (1) | DK2225393T3 (enExample) |
| ES (1) | ES2537625T3 (enExample) |
| IL (1) | IL206542A0 (enExample) |
| NZ (1) | NZ586373A (enExample) |
| RU (1) | RU2010131166A (enExample) |
| WO (1) | WO2009083763A1 (enExample) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016529915A (ja) * | 2013-09-16 | 2016-09-29 | ゼネラル・エレクトリック・カンパニイ | オリゴカチオン複合プライマー配列を使用する等温増幅 |
| JP2022512795A (ja) * | 2018-10-22 | 2022-02-07 | バイオニア コーポレーション | オクタミン又はオクタミン誘導体が結合したプローブ及びその用途 |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011108930A1 (en) | 2010-03-04 | 2011-09-09 | Interna Technologies Bv | A MiRNA MOLECULE DEFINED BY ITS SOURCE AND ITS DIAGNOSTIC AND THERAPEUTIC USES IN DISEASES OR CONDITIONS ASSOCIATED WITH EMT |
| EP2591106A1 (en) | 2010-07-06 | 2013-05-15 | InteRNA Technologies B.V. | Mirna and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated braf pathway |
| CN103080310A (zh) * | 2010-09-10 | 2013-05-01 | 三菱化学美迪恩斯株式会社 | 使用光的核酸的扩增抑制方法和高灵敏度的选择性核酸扩增方法 |
| EP2474617A1 (en) | 2011-01-11 | 2012-07-11 | InteRNA Technologies BV | Mir for treating neo-angiogenesis |
| WO2013095132A1 (en) | 2011-12-22 | 2013-06-27 | Interna Technologies B.V. | Mirna for treating head and neck cancer |
| KR102146523B1 (ko) * | 2012-01-06 | 2020-08-20 | 조원창 | 표적 핵산의 향상된 증폭 |
| WO2014072357A1 (en) | 2012-11-06 | 2014-05-15 | Interna Technologies B.V. | Combination for use in treating diseases or conditions associated with melanoma, or treating diseases or conditions associated with activated b-raf pathway |
| DE102017123919A1 (de) | 2017-10-13 | 2019-04-18 | Gna Biosolutions Gmbh | Verfahren und Vorrichtung zur Lyse von Mikroorganismen |
| CN111566212A (zh) | 2017-11-03 | 2020-08-21 | 因特尔纳技术有限公司 | miRNA分子，等同物，安塔够妙或其来源用于治疗和/或诊断与神经元缺陷相关的病症和/或疾病或用于神经元生成和/或再生 |
| JP2021513508A (ja) | 2018-02-12 | 2021-05-27 | インテアールエヌエー テクノロジーズ ビー．ヴイ．ＩｎｔｅＲＮＡ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｂ．Ｖ． | 抗がんマイクロｒｎａ及びその脂質製剤 |
| CN113444778A (zh) | 2020-03-27 | 2021-09-28 | 广州达安基因股份有限公司 | 具有高杂交性能的寡核苷酸缀合物及其应用 |
| IT202200026595A1 (it) | 2022-12-22 | 2024-06-22 | Fond Telethon Ets | Nuovi inibitori di regolatori epigenetici |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007069092A2 (en) * | 2005-12-15 | 2007-06-21 | Centre National De La Recherche Scientifique (Cnrs) | Cationic oligonucleotides, automated methods for preparing same and their uses |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1013770A1 (en) * | 1998-12-23 | 2000-06-28 | Université Louis Pasteur de Strasbourg | Non-viral transfection vector |
| CA2581869A1 (en) * | 2004-11-04 | 2006-05-18 | Raul Andino | Syntheses of polyamine conjugates of small interfering rnas (si-rnas) and conjugates formed thereby |
-
2007
- 2007-12-27 EP EP07025148A patent/EP2075342A1/en not_active Withdrawn
-
2008
- 2008-09-12 EP EP08868164.8A patent/EP2225393B1/en active Active
- 2008-09-12 RU RU2010131166/10A patent/RU2010131166A/ru not_active Application Discontinuation
- 2008-09-12 AU AU2008345460A patent/AU2008345460A1/en not_active Abandoned
- 2008-09-12 US US12/735,261 patent/US8465920B2/en active Active
- 2008-09-12 BR BRPI0821698-3A patent/BRPI0821698A2/pt not_active IP Right Cessation
- 2008-09-12 DK DK08868164.8T patent/DK2225393T3/en active
- 2008-09-12 JP JP2010540181A patent/JP2011507542A/ja active Pending
- 2008-09-12 CA CA2709183A patent/CA2709183A1/en not_active Abandoned
- 2008-09-12 ES ES08868164.8T patent/ES2537625T3/es active Active
- 2008-09-12 WO PCT/IB2008/002789 patent/WO2009083763A1/en not_active Ceased
- 2008-09-12 NZ NZ586373A patent/NZ586373A/xx not_active IP Right Cessation
- 2008-09-12 CN CN2008801227617A patent/CN101978071A/zh active Pending
- 2008-09-12 KR KR1020107015189A patent/KR20100124705A/ko not_active Withdrawn
-
2010
- 2010-06-22 IL IL206542A patent/IL206542A0/en unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007069092A2 (en) * | 2005-12-15 | 2007-06-21 | Centre National De La Recherche Scientifique (Cnrs) | Cationic oligonucleotides, automated methods for preparing same and their uses |
Non-Patent Citations (1)
| Title |
|---|
| JPN6013043509; Ｃｈｅｍｂｉｏｃｈｅｍ Ｖｏｌ．７， Ｎｏ．８, 2006, ｐｐ．１１７３-１１７６ * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016529915A (ja) * | 2013-09-16 | 2016-09-29 | ゼネラル・エレクトリック・カンパニイ | オリゴカチオン複合プライマー配列を使用する等温増幅 |
| JP2022512795A (ja) * | 2018-10-22 | 2022-02-07 | バイオニア コーポレーション | オクタミン又はオクタミン誘導体が結合したプローブ及びその用途 |
Also Published As
| Publication number | Publication date |
|---|---|
| IL206542A0 (en) | 2010-12-30 |
| AU2008345460A1 (en) | 2009-07-09 |
| US8465920B2 (en) | 2013-06-18 |
| CA2709183A1 (en) | 2009-07-09 |
| CN101978071A (zh) | 2011-02-16 |
| RU2010131166A (ru) | 2012-02-10 |
| BRPI0821698A2 (pt) | 2015-06-16 |
| EP2075342A1 (en) | 2009-07-01 |
| WO2009083763A1 (en) | 2009-07-09 |
| EP2225393A1 (en) | 2010-09-08 |
| EP2225393B1 (en) | 2015-02-25 |
| NZ586373A (en) | 2012-09-28 |
| DK2225393T3 (en) | 2015-05-26 |
| US20100311056A1 (en) | 2010-12-09 |
| KR20100124705A (ko) | 2010-11-29 |
| ES2537625T3 (es) | 2015-06-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8465920B2 (en) | Method for hybridizing nucleic acids | |
| CA2486420C (en) | Compositions and methods for detecting hepatitis b virus | |
| CA2692633C (en) | Method for the simultaneous detection of multiple nucleic acid sequences in a sample | |
| AU741141B2 (en) | Specific and sensitive method for detecting nucleic acids | |
| JP4782668B2 (ja) | 日本脳炎ウィルス血清グループのメンバーを包含する一定のフラビウィルスを検出するための組成物及び方法 | |
| CN106574304B (zh) | 基于链侵入的dna扩增方法 | |
| JP2006523460A (ja) | 試料中のｓａｒｓコロナウイルスの存在を決定するための組成物および方法 | |
| CN101379196A (zh) | 用于鉴定临床样品中的人乳头瘤病毒的体外诊断试剂盒 | |
| US20050176014A1 (en) | Fluorescent hybridization probes with reduced background | |
| WO2013028316A2 (en) | Compositions, methods, and kits for nucleic acid hybridization | |
| JP2024116383A5 (enExample) | ||
| JP7469290B2 (ja) | エプスタイン－バールウイルスの核酸を検出するための組成物および方法 | |
| JP5299964B2 (ja) | Ｄｎａ３’末端の修飾基除去用酵素試薬 | |
| WO2003083142A2 (en) | UNIVERSAL DETECTION OF HUMAN PAPILLOMAVIRUS mRNA | |
| JP7542546B2 (ja) | ヒトポリオーマウイルスｂｋウイルスを増幅、検出または定量化するための組成物および方法 | |
| US20140193803A1 (en) | Methods, compositions, and kits for determining hepatitus a virus | |
| US8158345B2 (en) | Labeled oligonucleotide | |
| WO2024137379A2 (en) | Compositions and methods for detecting gastrointestinal pathogens | |
| HK1195786B (en) | Methods, compositions, and kits for determining hepatitis a virus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110801 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20110801 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130903 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20140218 |